11Jun 2022
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study

Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study

The objective of this study was to evaluate the cost-utility of MITs (WVTT and PUL) compared to pharmacotherapy as an initial treatment for patients with moderate-to-severe BPH. WVTT is an effective and cost-saving procedure and may be an appropriate first-line alternative to pharmacotherapy for moderate-to-severe BPH patients who seek faster improvement and have no lifelong commitment to daily medications.

  • #urology

Like

Save

Share